Clinical Trial Update: Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating a combination of PD-1 blockade, CD137 agonism, and adoptive cell therapy for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Adoptive cell therapy
• CD137 agonist
• PD-1 blockade agent

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma (Skin), Skin Cancer | EARLY_Phase 1 | Status: COMPLETED